Overview

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-12-01

Target enrollment:

Participant gender:

Summary

To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.

Phase:

PHASE3

Details

Lead Sponsor:

Intensity Therapeutics, Inc.

Collaborator:

Premier Research Group plc

Treatments:

eribulin
pazopanib
Trabectedin